Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

• Main Authors: Philip J. Kuehl (Author), Marcie J. Grimes (Author), Devon Dubose (Author), Michael Burke (Author), David A. Revelli (Author), Andrew P. Gigliotti (Author), Steven A. Belinsky (Author), Mathewos Tessema (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase local exposure and efficacy against lung cancer whi...